Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
According to TipRanks, Butler is an analyst with an average return of -6.1% and a 36.60% success rate. Butler covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cytokinetics, and Halozyme.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $701.18, a 4.59% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $772.00 price target.
ARGX market cap is currently $39.87B and has a P/E ratio of -187.54.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.